NCT05096364 - A Phase 2 Study of Efficacy and Safety of AK111 in Subjects With Moderate-to-Severe Psoriasis | Biotech Hunter

Enrollment

251

Participants

Timeline

Start Date

April 28, 2021

Primary Completion Date

February 3, 2023

Study Completion Date

February 3, 2023

Conditions

Psoriasis

Interventions

BIOLOGICAL

AK111/Placebo

After loading dose, investigational drug was administered subcutaneously up to 60 weeks.

Trial Locations (13)

AkesoBio Investigative Site 1011, Bengbu

AkesoBio Investigative Site 1009, Beijing

AkesoBio Investigative Site 1016, Beijing

AkesoBio Investigative Site 1003, Guangzhou

AkesoBio Investigative Site 1007, Guangzhou

AkesoBio Investigative Site 1012, Chengde

AkesoBio Investigative Site 1018, Harbin

AkesoBio Investigative Site 1008, Changsha

AkesoBio Investigative Site 1013, Yancheng

AkesoBio Investigative Site 1001, Shanghai

AkesoBio Investigative Site 1010, Shanghai

AkesoBio Investigative Site 1002, Hanzhou

AkesoBio Investigative Site 1006, Ningbo